Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in significant eyelash growth.
The company has said that if approved by the FDA, Allergan’s bimatoprost product for eyelash growth will be available by prescription only to consumers in the US.
Scott Whitcup, executive vice president of R&D at Allergan, said: “Our exploration of bimatoprost as an eyelash growth enhancer reflects our continuing commitment to offer innovative medical aesthetic treatments that are science-based, with the clinically proven safety and efficacy that consumers have come to trust Allergan to provide.”